FDA clears SmartCapnoLine O2 capnography device for use in sedated, non-intubated patients to detect potentially fatal adverse events that can occur during sedation including apnea, ventilatory depression and airway obstruction. The product is in compliance with updated 2001 Joint Commission on Accreditation of Healthcare Organizations standards that call for monitoring ventilation in patients...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
